Comera Life Sciences Holdings Inc
Change company Symbol lookup
Select an option...
CMRA Comera Life Sciences Holdings Inc
ADI Analog Devices Inc
KEY KeyCorp
FNF Fidelity National Financial Inc
CTAQU Carney Technology Acquisition Corp. II
MUE BlackRock MuniHoldings Quality Fund II, Inc.
NC NACCO Industries Inc
RXT Rackspace Technology Inc
THCHW TH International Equity Warrant Exp 28th Sept 2027 *W EXP 09/28/2027
PFLT PennantPark Floating Rate Capital Ltd
Go

Company profile

Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company is engaged in developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Its proprietary formulation platform, SQore, is designed to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. The platform optimizes current versions of subcutaneous biologics and produce biosimilar versions of existing subcutaneous products. It has the potential for broad applications in therapeutic areas dependent on protein-based biologic treatments. The SQore platform includes proprietary structural calculations combined with analytical measurements to guide the selection of excipients for a given protein. The Company’s product programs: CLS-001, a preclinical stage biobetter for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.

Price
Delayed
$1.84
Day's Change
-0.0876 (-4.54%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.11
Day's Low
1.82
Volume
(Below Average)

Today's volume of 165,133 shares is on pace to be lower than CMRA's 10-day average volume of 337,022 shares.

165,133

Zentek Files a Provisional Patent on the use of ZenGUARD(TM) as an Anti-Inflammatory Agent

8:00 am ET July 18, 2022 (Accesswire) Print

GUELPH, ON / ACCESSWIRE / July 18, 2022 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, has filed a provisional patent on the use of ZenGUARDT as an anti-inflammatory agent for dermatological conditions.



"We continue to work diligently to secure patents for our various intellectual property," said Greg Fenton, CEO for Zentek. "This is another demonstration of how we are further commercializing our unique ZenGUARDT technology, which is already well-researched, developed, and authorized by Health Canada for use as an antimicrobial agent on surgical masks and other PPE."

ZenGUARDT, as a dermatological product, is currently being researched for treatment of various skin conditions, including both infectious and inflammatory conditions like acne, psoriasis, eczema, sunburn, poison ivy, warts, seborrheic dermatitis and toenail fungal infections. As reported March 10th, 2022, Zentek is conducting pre-clinical research with Vimta Labs to collect data that is required for the submission of an Investigational New Drug to the United States Food and Drug Administration (FDA), a requirement for the administration of new drugs in humans.



About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. Zentek is currently focused on commercializing ZenGUARDT, a patent-pending coating shown to have over 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.



For further information:

Tyler Dunn

Tel: (306) 717-6745

Email: tdunn@zentek.com

To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at http://www.sedar.com/.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zentek Ltd.





View source version on accesswire.com:

https://www.accesswire.com/708866/Zentek-Files-a-Provisional-Patent-on-the-use-of-ZenGUARDTM-as-an-Anti-Inflammatory-Agent



comtex tracking

COMTEX_410462456/2457/2022-07-18T08:00:30

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.